Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Celebrates European Ryaltris Approvals

Has Marketing Authorizations In 13 European Countries; Menarini Set To Launch

Executive Summary

Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.

You may also be interested in...



Glenmark Expects ‘Strong Year’ With ‘First’ EU Spiriva Rival Imminent

Glenmark said it would continue to deliver new respiratory products in Europe moving forward as the Indian firm lines up what it believes will be the first generic version of Boehringer Ingelheim’s Spiriva Handihaler.

Glenmark’s Ryaltris To Reach Western Europe Following Approvals

Glenmark is toasting another launch for the company’s Ryaltris novel treatment for allergic rhinitis, this time with plans to roll the product out in 17 countries across western Europe.

Glenmark’s Ryaltris Close To Entry In Major Eastern Europe Market

Having divested a basket of allergy treatments in Russia and the CIS to Dr Reddy’s last year, Glenmark is gearing up to launch its novel Ryaltris nasal spray in a major Eastern Europe market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel